SALUS TV NUMERO 52 ANNO XIX – 27 dicembre 2023
(Adnkronos) - In questo numero: Congresso Sigo 2023, al centro la donna e la sua salute per un futuro migliore; Marilab Center di Ostia presenta nuova Risonanza magnetica da 3 tesla confermando innovazione e progresso nel settore; Quarantacinque anni di Servizio sanitario nazionale, esperti, imprese e associazioni a confronto tra traguardi e sfide future; L’appello del Cnel, prevenire con la “Cancer Driver Interception”; AbbVie presenta nuova terapia che rivoluziona concetto tempo per paziente con leucemia linfatica cronica; Volpi Rosse Menarini, amore per il basket senza barriere; OncoVoice, da persone con tumore della prostata e caregiver richieste informazioni su patologia a 360°
Category
🗞
NewsTranscript
00:00 [MUSIC PLAYING]
00:03 [MUSIC PLAYING]
00:06 [MUSIC PLAYING]
00:11 [SPEAKING ITALIAN]
00:14, Cancer Driver Interception.
00:43 [SPEAKING ITALIAN]
00:46 [SPEAKING ITALIAN]
00:59 OncoVoice.
01:00 [SPEAKING ITALIAN]
01:12 [SPEAKING ITALIAN]
01:15 [SPEAKING ITALIAN]
01:28 [SPEAKING ITALIAN]
01:30 [SPEAKING ITALIAN]
01:54 [SPEAKING ITALIAN]
02:05 [SPEAKING ITALIAN]
02:07 [SPEAKING ITALIAN]
02:25 [SPEAKING ITALIAN]
02:55 [SPEAKING ITALIAN]
03:02 [SPEAKING ITALIAN]
03:08 [SPEAKING ITALIAN]
03:15 [SPEAKING ITALIAN]
03:39 [SPEAKING ITALIAN]
03:41 [SPEAKING ITALIAN]
04:08 [SPEAKING ITALIAN]
04:32 [SPEAKING ITALIAN]
04:58 [SPEAKING ITALIAN]
05:23 [SPEAKING ITALIAN]
05:36 [SPEAKING ITALIAN]
05:38 [SPEAKING ITALIAN]
05:49 [SPEAKING ITALIAN]
05:50 [SPEAKING ITALIAN]
06:15 [SPEAKING ITALIAN]
06:16 [SPEAKING ITALIAN]
06:30 [SPEAKING ITALIAN]
06:31 [SPEAKING ITALIAN]
06:55 [SPEAKING ITALIAN]
06:56 [SPEAKING ITALIAN]
07:12 [SPEAKING ITALIAN]
07:13 [SPEAKING ITALIAN]
07:25 [SPEAKING ITALIAN]
07:26 [SPEAKING ITALIAN]
07:48 [SPEAKING ITALIAN]
07:49 [SPEAKING ITALIAN]
07:59 [SPEAKING ITALIAN]
08:00 [SPEAKING ITALIAN]
08:11 [SPEAKING ITALIAN]
08:12 [SPEAKING ITALIAN]
08:24 [SPEAKING ITALIAN]
08:25 [SPEAKING ITALIAN]
08:26 [SPEAKING ITALIAN]
08:40 [SPEAKING ITALIAN]
08:41 [SPEAKING ITALIAN]
08:42 [SPEAKING ITALIAN]
09:06 [SPEAKING ITALIAN]
09:17 [SPEAKING ITALIAN]
09:18 [SPEAKING ITALIAN]
09:42 [SPEAKING ITALIAN]
10:11 [SPEAKING ITALIAN]
10:22 [SPEAKING ITALIAN]
10:24 [SPEAKING ITALIAN]
10:35 [SPEAKING ITALIAN]
10:36 [SPEAKING ITALIAN]
10:50 [SPEAKING ITALIAN]
10:51 [SPEAKING ITALIAN]
11:14 [SPEAKING ITALIAN]
11:42 [SPEAKING ITALIAN]
11:50 [SPEAKING ITALIAN]
11:52 [SPEAKING ITALIAN]
12:06 [SPEAKING ITALIAN]
12:07 [SPEAKING ITALIAN]
12:31 [SPEAKING ITALIAN]
12:40 [SPEAKING ITALIAN]
12:41 [SPEAKING ITALIAN]
13:02 [SPEAKING ITALIAN]
13:31 [SPEAKING ITALIAN]
13:32 [SPEAKING ITALIAN]
14:01 [SPEAKING ITALIAN]
14:20 [SPEAKING ITALIAN]
14:50 both the patient's quality of life, which is the first thing for us, and the doctor's management, who can manage more patients at the same time.
14:59 The approach of the past immune-therapy camp led the patient to have significant side effects,
15:04 especially in terms of infections, more frequent in the elderly patient, therefore more fragile at the immune level,
15:10 impact of the more modest infections, instead, with the therapy of the present.
15:14 In addition, the older patient, but also the young one, due to the immune-therapy camp,
15:22 could suffer from cytopenia, therefore anemia, therefore need for transfusion support, granulocytopenia,
15:32 therefore an increase in the risk of infection.
15:35 All these side effects are greatly resized with a more specific therapeutic approach,
15:44 more aimed at those that are the mechanisms that are the cause of the proliferation of the heliocentric cells
15:52 and their prolonged survival.
15:56 In the use of this new therapeutic paradigm, the real challenge is to allow the use of drugs
16:01 that guarantee a low profile of toxicity.
16:04 And since these diseases are actually comorbid, that is, they have many concomitant diseases,
16:10 we must have drugs that, by affecting the disease, do not worsen the general conditions.
16:15 New drugs are succeeding.
16:17 Venetoclax, for example, is able to give excellent responses with a very low profile of toxicity.
16:24 This has a strong impact and, above all, extends the possibility of therapy to a very wide range of diseases,
16:31 especially those very old.
16:34 What is the spirit of the Menarini Volpi Rosse?
16:37 Perseverance, courage and a love for sport that knows no barriers.
16:44 This is the spirit of the Menarini Volpi Rosse, the first Tuscan basketball team in the carrier,
16:49 born in 2005 thanks to the Welsh Air Sport Association Florence.
16:56 The Menarini Volpi Rosse is a basketball team in the carrier, an ASD, which was born in 2005
17:04 following the accident of one plus one, let's say, of two basketball players
17:11 who unfortunately had their misfortune relegated to a carrier.
17:15 A group of friends, not too close, proposed to us to try to do something related to basketball for these guys.
17:24 So the then Association of Social Promotion was born, Volpi Rosse Menarini.
17:31 2011 is also the year that marks the change of pace of the Volpi Rosse thanks to the meeting with Menarini,
17:37 which becomes the team's main sponsor, with which an extraordinary journey begins,
17:41 made of determination, resilience and team spirit and important results,
17:46 such as the championship victory in 2021.
17:49 A very young group, we can really boast of being the youngest team in our league,
17:55 made up of very promising guys, talents, we work and we are working at our best.
18:02 Currently the Menarini Volpi Rosse has about 16 athletes, of which 4 are from the Italian national team.
18:08 All athletes models of internal strength, team spirit and solidarity.
18:13 This group, being a very young group, knowing a little everyone, inspired me a lot of confidence and so I wanted to come here.
18:20 I got my hands dirty and starting from scratch, then I said to myself, come on, we can do it and now I have arrived here.
18:29 I think this is a great young team with a lot of potential, of which I wanted to be part.
18:35 And I think this project with coach Fabio has a lot of potential and that's why I joined this team.
18:42 This is my third year that I have been playing here and I love Firenze, I love my team and I hope there will be other European Championships
18:52 and I hope in the future we will be champions in Serie A and also in the European Cup.
18:58 But the greatness of this team does not come from the sporting results.
19:02 Since 2013, the Volpi Rosse have been active in the schools of the first and second grades of Firenze,
19:07 with various projects on disability, inclusion and social integration.
19:12 The quality of life is one of the areas most called into question by patients with prostate cancer,
19:29 which highlights the need for more information on pathology, diagnosis and management,
19:35 as well as its prevention and treatment.
19:37 And how much emerges from the 1,288 posts collected by the Quantitative Equality Survey
19:42 on the biopsychosocial aspects that characterize patients and their caregivers,
19:46 analyzing the comments and actions of the OncoVoice community users.
19:51 A section of the Janssen.com.it portal dedicated to prostate lung tumors,
19:56 established by Janssen, a pharmaceutical company of the Johnson & Johnson group.
20:00 But what do people in particular look for?
20:03 Information on pathologies, diagnosis, treatments,
20:10 but also information on the type of services available within the national territory.
20:15 One of the most common requests is to understand which are the centers of excellence
20:19 where, for example, prostate cancer is diagnosed and treated.
20:24 Not only this, but also information on costs, for example,
20:29 and then also a desire to be part of a community
20:36 where a series of opinions, questions, doubts and sharings of what they are sharing
20:44 can be exchanged, which is not at all banal or easy.
20:47 And within this system we have also set up a service called "The expert answers".
20:52 So patients or caregivers can ask a doctor
20:56 who makes himself available for a certain time frame
21:00 and provides answers to the questions they are asked.
21:03 This is because we realize that patients and their families
21:07 are always looking, especially in the online world,
21:11 for a whole series of information when they receive a diagnosis
21:15 or simply have suspicions because they have taken exams.
21:18 And so we believe that as a company engaged in this sector
21:23 it is important that they find the most accurate and most referenced information
21:28 and that they are therefore absolutely reliable.
21:30 The service "The expert answers" is also on the Facebook page
21:34 and on the OncoVoice Instagram account.
21:36 Most of the posts have been published by the patients themselves,
21:40 often people already with a prostate tumor,
21:42 but there are also contributions from caregivers,
21:45 in particular women, spouses or relatives,
21:48 who remember their loved ones who lost their lives to the pathology.
21:51 The prostate cancer interests in fact about 564,000 Italians,
21:56 according to the IOM data, the Italian Association of Medical Oncology,
22:00 and it is the most common tumor in men,
22:03 with about 40,509 cases per year,
22:06 equal to 19.8% of all male tumors.
22:09 In 2022, in our country, 7,200 deaths were estimated for this pathology,
22:15 although overall the healing fraction today exceeds 75%,
22:19 and not considering mortality for other causes,
22:22 the value is estimated at 91% 5 years after diagnosis.
22:26 However, only 13.2% of the posts refer to the improvements to the treatments.
22:34 Therefore, the need to pay attention to both the active and post-treatment phases,
22:40 facing the issue of the effectiveness of anti-cancer treatments
22:43 and the associated side effects.
22:47 And what else has the investigation highlighted?
22:49 The most important result concerns mainly the medical sphere.
22:54 Most of the contents are about the pathology of the prostate tumor.
23:00 For this reason, we mean the medical sphere,
23:02 we also mean the biology of the prostate tumor.
23:04 Many questions are also why the prostate tumor is there,
23:08 although very important are also the psychological developments.
23:12 Much more often, it is easier for patients to face an online platform
23:16 than with the doctor.
23:18 Psychological aspects, such as anger, fear, sadness,
23:21 as the patient with the prostate tumor faces during the course,
23:25 but sometimes also those topics that are not discussed during a patient's interview,
23:29 such as those of the sexual sphere,
23:31 where there are many cultural prejudices that the patient does not tend to face during the visit,
23:35 and then searches online for a solution.
23:37 Very important are also, for example, the questions that are asked about screening.
23:41 Sometimes, some are also worrying.
23:43 There have been comments in which screening is only business.
23:47 If you think about it, there is a lot of prejudice,
23:49 because as you know, the woman goes to her gynecologist for prevention,
23:53 she has several annual checks,
23:55 the man, on the other hand, is a little more restive, he does not have a reference urologist.
23:58 Generally, he goes to the urologist when he has a urological problem,
24:00 sometimes when it is too late.
24:02 And this, these platforms with dedicated fads and podcasts,
24:07 must try to change the cultural attitude that man has when confronting the urologist.
24:12 To break down those barriers in which man relies on a urologist
24:16 to try to do prevention,
24:18 avoid that the problem is verified,
24:20 and avoid that it is too late for a solution to the problem.
24:23 This was our last news.
24:31 To contact us, you can write to salute@dnchronos.com
24:37 Thank you for following us
24:39 and from the whole editorial staff, many wishes of a good 2024!
24:43 www.dnchronos.com